Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?

C Russell, S Lange, F Kouyoumdjian, A Butler… - Harm Reduction …, 2022 - Springer
Opioid agonist treatment (OAT) is the primary intervention for opioid use disorder (OUD) in
Canada and the USA. Yet, a number of barriers contribute to sub-optimal treatment uptake …

Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives

SV Aronowitz, E Engel-Rebitzer, A Dolan… - Harm reduction …, 2021 - Springer
Background The majority of individuals with opioid use disorder (OUD) face access barriers
to evidence-based treatment, and the COVID-19 pandemic has exacerbated the United …

Assessment of community-level vulnerability and access to medications for opioid use disorder

PJ Joudrey, M Kolak, Q Lin, S Paykin… - JAMA network …, 2022 - jamanetwork.com
Importance Given that COVID-19 and recent natural disasters exacerbated the shortage of
medication for opioid use disorder (MOUD) services and were associated with increased …

Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior

P Mitchell, S Samsel, KM Curtin, A Price… - Social Science & …, 2022 - Elsevier
Drug overdose is the leading cause of accidental death in the US with deaths from opioid
overdose occurring at a higher rate in rural areas. The gaps in the provision of healthcare …

Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth …

A Sivakumar, L Madden, E DiDomizio, A Eller… - International Journal of …, 2022 - Elsevier
Background Healthcare delivery was disrupted during the COVID-19 pandemic, requiring
minimized in-person contact between patients and clinicians. During the pandemic, people …

[HTML][HTML] Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in …

D Aldabergenov, L Reynolds, J Scott… - International Journal of …, 2022 - Elsevier
Background The coronavirus pandemic resulted in many changes which had the potential to
impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine) …

[HTML][HTML] The global, regional, and national burden and trends of NAFLD in 204 countries and territories: an analysis from global burden of disease 2019

H Chen, Y Zhan, J Zhang, S Cheng… - JMIR public health …, 2022 - publichealth.jmir.org
Background Nonalcoholic fatty liver disease (NAFLD) poses a substantial socioeconomic
burden and is becoming the fastest growing driver of chronic liver disease, potentially …

Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review

V Panwala, P Joudrey, M Kowalski, P Bach… - Journal of Substance Use …, 2023 - Elsevier
Introduction In response to the COVID-19 pandemic, countries across the world made
adaptations to policies regulating the provision of methadone maintenance therapy (MMT) to …

The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months

AS Bennett, T Townsend, L Elliott - International Journal of Drug Policy, 2022 - Elsevier
Background Concurrent opioid-related overdose and COVID-19 crises in the US have
imposed unprecedented challenges on people who use illicit opioids. Methods Using the …

[HTML][HTML] Typology of laws restricting access to methadone treatment in the United States: a latent class analysis

A Conway, N Krawczyk, F McGaffey, S Doyle… - International Journal of …, 2023 - Elsevier
Abstract Background In the United States, methadone treatment for opioid use disorder is
only available at opioid treatment programs (OTPs). In addition to federal regulations, states …